The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial
Abstract
SUMMARY Aims To compare the efficacy of insulin aspart, a rapid‐acting insulin analogue, with that of unmodified human insulin on long‐term blood glucose control in Type 1 diabetes mellitus. Methods Prospective, multi‐centre, randomized, open‐labelled, parallel‐group trial lasting 6 months in 88 centres in eight European countries and including 1070 adult subjects with Type 1 diabetes. Study patients were randomized 2:1 to insulin aspart or unmodified human insulin before main meals, with NPH‐insulin as basal insulin. Main outcome measures were blood glucose control as assessed by HbA 1c, eight‐point self‐monitored blood glucose profiles, insulin dose, quality of life, hypoglycaemia, and adverse events. Results After 6 months, insulin aspart was superior to human insulin with respect to HbA 1c with a baseline‐adjusted difference in HbA 1c of 0.12 (95% confidence interval 0.03–0.22) %Hb, P < 0.02. Eight‐point blood glucose profiles showed lower post‐prandial glucose levels (mean baseline‐adjusted −0.6 to −1.2 mmol/l, P < 0.01) after all main meals, but higher pre‐prandial glucose levels before breakfast and dinner (0.7–0.8 mmol/l, P < 0.01) with insulin aspart. Satisfaction with treatment was significantly better in patients treated with insulin aspart (WHO Diabetes Treatment Satisfaction Questionnaire (DTSQ) baseline‐adjusted difference 2.3 (1.2–3.3) points, P < 0.001). The relative risk of experiencing a major hypoglycaemic episode with insulin aspart compared to human insulin was 0.83 (0.59–1.18, NS). Major night hypoglycaemic events requiring parenteral treatment were less with insulin aspart (1.3 vs. 3.4% of patients, P < 0.05), as were late post‐prandial (4–6 h) events (1.8 vs. 5.0% of patients, P < 0.005). Conclusions These results show small but useful advantage for the rapid‐acting insulin analogue insulin aspart as a tool to improve long‐term blood glucose control, hypoglycaemia, and quality of life, in people with Type 1 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873
Cited by
Owens, D. R., Zinman, B., & Bolli, G. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05842-1 · Cited by 373
Hermansen, K., Fontaine, P., Kukolja, K. K., Peterkova, V., Leth, G., & Gall, M.-A. (2004) · Diabetologia · doi:10.1007/s00125-004-1365-z · Cited by 365
The use of unequal randomisation ratios in clinical trials: A review
Dumville, J. C., Hahn, S., Miles, J. N. V., & Torgerson, D. J. (2006) · Contemporary Clinical Trials · doi:10.1016/j.cct.2005.08.003 · Cited by 320
Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., Kristensen, A., & Draeger, E. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.590 · Cited by 294
Zaykov, A. N., Mayer, J. P., & DiMarchi, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.36 · Cited by 287
Metadata
- Authors
- Home, P. D., Lindholm, A., Riis, A., & for the European Insulin Aspart Study Group
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2000-11
- Volume
- 17
- Issue
- 11
- Pages
- 762-770
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2160252336
- Cited by
- 232
- References
- 1
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. https://app.cochat.ai/papers/10.1046/j.1464-5491.2000.00380.x
- The paper
- Home, P. D., Lindholm, A., Riis, A., & for the European Insulin Aspart Study Group. (2000). Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabetic Medicine. https://doi.org/10.1046/j.1464-5491.2000.00380.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.